Test a device to choose the first chemo for metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have confirmed colorectal adenocarcinoma that has spread (metastatic disease), with at least one measurable spot
- Your cancer doctor says you can use standard chemo plans like FOLFOX/FOLFIRI/FOLFIRINOX (with or without certain targeted medicines, depending on your tumor markers)
- You are able to have the Oncogramme® test done, and you’re generally well enough (WHO health status 0 to 2, expected survival over 3 months)
- Your blood and organ tests are within limits (enough white blood cells, platelets, hemoglobin; and acceptable liver, kidney, and electrolyte levels)
- You have not had prior chemotherapy before (except certain past peri-operative/adjuvant chemo that ended more than 6 months ago)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new combination therapy (PM8002 plus chemotherapy) for people with metastatic colorectal cancer who have not had prior treatment. It may be an option if your cancer is not MSI-H/dMMR and you are in good overall health.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
This Phase 2 trial tests whether bevacizumab plus oxaliplatin and TAS-102 works better and is safe as the first treatment for advanced colorectal (colon/rectum) cancer. You may be asked to meet specific health and blood-test requirements and avoid other cancer treatments during the study.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.